Emzale-L

Description

Emzale-L is a combination formulation containing esomeprazole 40 mg as delayed-release pellets and levosulpiride 75 mg as extended-release pellets. Esomeprazole reduces stomach acid production, while levosulpiride acts on dopamine receptors and may influence upper gastrointestinal motility.

A healthcare professional may consider this combination for selected acid-related gastrointestinal conditions accompanied by motility-related symptoms, when both ingredients are clinically appropriate. Levosulpiride can cause neurological and hormonal adverse effects, so treatment requires appropriate medical supervision.

Emzale-L is listed in the General Physician (G.P.) and Gynae product segments and is supplied in Alu-Alu packaging of 10 × 10 units.

Therapeutic Segment

Gastroenterology | Acid-Related Disorders | Gastrointestinal Motility

Uses of Emzale-L

A healthcare professional may consider Emzale-L for selected patients with:

• Acid-related upper gastrointestinal symptoms requiring acid suppression.
• Gastro-oesophageal reflux symptoms, where the formulation is appropriate.
• Upper gastrointestinal discomfort associated with impaired motility, when levosulpiride is clinically indicated.
• Combined acid-related and motility symptoms requiring individual assessment.

The exact indication depends on the diagnosis and approved product information. Not every case of acidity, bloating or indigestion requires this combination.

Key Benefits

• Acid Suppression: Esomeprazole reduces gastric acid secretion.
• Motility-Related Symptom Support: Levosulpiride may affect upper gastrointestinal motility in selected patients.
• Complementary Pharmacological Actions: The two ingredients act through different mechanisms.
• Modified-Release Formulation: The supplied composition identifies esomeprazole as delayed-release pellets and levosulpiride as extended-release pellets.
• Convenient Packaging: Supplied in Alu-Alu packaging of 10 × 10 units.

The benefits depend on the patient’s condition and the suitability of the formulation. Treatment response is not guaranteed.

How Emzale-L Works

Esomeprazole belongs to the proton pump inhibitor (PPI) class. It suppresses the gastric proton pump in stomach cells, reducing acid secretion. The delayed-release formulation is designed to protect the ingredient from stomach acid and support its intended release.

Levosulpiride acts mainly through dopamine D2 receptor antagonism. Depending on the formulation and clinical context, it may affect upper gastrointestinal motility and certain associated symptoms. It can also cause central nervous system and hormonal adverse effects, which must be considered before treatment.

Possible Side Effects

Possible side effects may include:

• Headache.
• Abdominal discomfort.
• Nausea, diarrhoea or constipation.
• Dizziness or sleepiness.
• Restlessness or other movement-related symptoms.
• Increased prolactin levels, which may cause breast discharge, menstrual changes or sexual dysfunction.

Levosulpiride may cause serious movement disorders or other neurological effects, particularly with prolonged exposure or in susceptible patients. Seek medical advice if unusual movements, marked restlessness or hormonal symptoms develop. Obtain urgent medical attention for severe or rapidly worsening symptoms.

Important Safety Information

• Medical supervision: Use Emzale-L only as directed by a qualified healthcare professional.
• Neurological effects: Inform your prescriber about Parkinson’s disease, seizure disorders or a history of movement-related conditions.
• Hormonal effects: Levosulpiride can increase prolactin levels. Discuss unexplained menstrual changes, breast discharge or sexual dysfunction with a healthcare professional.
• Drowsiness: Avoid driving or operating machinery if the medicine causes sleepiness or dizziness.
• Drug interactions: Tell your healthcare professional about all medicines and supplements you take, particularly those that cause drowsiness or affect dopamine signalling.
• Pregnancy and breastfeeding: Seek medical advice before use.
• Persistent symptoms: Difficulty swallowing, recurrent vomiting, gastrointestinal bleeding, unexplained weight loss or severe abdominal pain require prompt medical evaluation.
• Avoid self-medication: Do not increase the dose or extend treatment without professional advice.

Dosage and Administration

Take Emzale-L only according to the prescription and approved product label. The appropriate dose, timing and duration depend on the patient’s diagnosis, medical history and formulation instructions.

Because the product contains delayed-release and extended-release pellets, follow the exact administration instructions on the approved label. Do not crush, chew or alter the pellets unless the product-specific instructions explicitly permit it.

Storage Instructions

Store Emzale-L according to the conditions stated on the approved product label. Keep the product in its original packaging, away from children, and do not use it after the expiry date.